Abstract: In a method for making an anion electrolyte membrane, an inorganic nano-powder is uniformly dispersed in an organic solvent to form a mixture. A fluorinated poly(aryl ether) ionomer is dissolved in the mixture to form a first solution. An active component is further dissolved in the first solution to form a second solution. A crosslinking catalyst is added to the second solution to form a membrane casting solution. The membrane casting solution is coated on a substrate to form a membrane, and the coated substrate is heated. Then, the membrane is peeled from the substrate.

Abstract: In a method for making anion electrolyte membrane a fluorinated poly(aryl ether) ionomer is dissolved in a solvent to form a ionomer solution. A crosslink component is added to the ionomer solution, to achieve a transparent solution. An inorganic component precursor and water are introduced to the transparent solution, to form a sol-gel mixture. A crosslink catalyst is mixed with the sol-gel mixture to form a membrane casting solution. The membrane casting solution is coated on a substrate to form a membrane, and heated. The membrane is removed from the substrate.

Abstract: A method for making lithium iron phosphate is provided. In the method, an alkali is reacted with a ferric salt in water to form a red colored ferric hydroxide precipitate in the water. The red colored ferric hydroxide precipitate is mixed with deionized water, organic solvent, and emulsifier to form an water-in-oil emulsion. The phosphoric acid solution and iron metal powder are added to the water-in-oil emulsion to form ferrous hydrogen phosphate. A lithium source is introduced to the water-in-oil emulsion and reacted with the ferrous hydrogen phosphate to form a precursor in the water-in-oil emulsion. The precursor is heated in a protective gas at a heating temperature in a range from about 600° C. to about 800° C. to form lithium iron phosphate.

Abstract: A method for producing polymerizable solution which comprises dissolving an ethylenically unsaturated zwitterionic monomer in a co-monomer system comprising a functionalized ethylenically unsaturated monomer in which the zwitterionic monomer is soluble, a siloxane group-containing monomer or macromer, and a crosslinking agent is disclosed. The polymerizable solution is biocompatible and can be used to produce polymers and articles such as contact lenses.

Abstract: In a method for making an anion electrolyte membrane, an inorganic nano-powder is uniformly dispersed in an organic solvent to form a mixture. A fluorinated poly(aryl ether) ionomer is dissolved in the mixture to form a first solution. An active component is further dissolved in the first solution to form a second solution. A crosslinking catalyst is added to the second solution to form a membrane casting solution. The membrane casting solution is coated on a substrate to form a membrane, and the coated substrate is heated. Then, the membrane is peeled from the substrate.

Abstract: A method for making lithium iron phosphate is provided. In the method, an alkali is reacted with a ferric salt in water to form a red colored ferric hydroxide precipitate in the water. The red colored ferric hydroxide precipitate is mixed with deionized water, organic solvent, and emulsifier to form an water-in-oil emulsion. The phosphoric acid solution and iron metal powder are added to the water-in-oil emulsion to form ferrous hydrogen phosphate. A lithium source is introduced to the water-in-oil emulsion and reacted with the ferrous hydrogen phosphate to form a precursor in the water-in-oil emulsion. The precursor is heated in a protective gas at a heating temperature in a range from about 600° C. to about 800° C. to form lithium iron phosphate.

Abstract: In a method for making anion electrolyte membrane a fluorinated poly(aryl ether) ionomer is dissolved in a solvent to form a ionomer solution. A crosslink component is added to the ionomer solution, to achieve a transparent solution. An inorganic component precursor and water are introduced to the transparent solution, to form a sol-gel mixture. A crosslink catalyst is mixed with the sol-gel mixture to form a membrane casting solution. The membrane casting solution is coated on a substrate to form a membrane, and heated. The membrane is removed from the substrate.

Abstract: A method for producing polymerisable solution which comprises dissolving an ethylenically unsaturated zwitterionic monomer in a co-monomer system comprising a functionalised ethylenically unsaturated monomer in which the zwitterionic monomer is soluble, a siloxane group-containing monomer or macromer, and a crosslinking agent is disclosed. The polymerisable solution is biocompatible and can be used to produce polymers and articles such as contact lenses.

Abstract: An implant, usually a stent, has a coating of a cross-linked water swellable polymer matrix preferably having a dry thickness of at least 0.1 &mgr;m, and a pharmaceutically active compound, the polymer having pendant cationic and pendant zwitterionic groups. The active is usually an anionic compound such as a nucleic acid. The polymer is peferably formed from 2-methacyloy-loxyethyl-2′-trimethylammoniumethyl phosphate inner salt, trialkylammoniumalkyl(meth)acrylate and a cross-linkable monomer such as &ohgr;-(trialkoxysilyl)alkyl(meth)acrylate, optionally with a termonomer such as a higher alkyl (meth)acrylate. The stent is coated with polymer, cross-linked then contacted with a solution or dispersion of active compound in a solvent which swells the polymer whereby the active is absorbed into the polymer matrix. The stent is delivered by usual means into a body lumen and the actives released over an extended period of time into the wall of the lumen and/or fluid flowing therein.

Abstract: An implant, usually a stent, has a coating of a cross-linked water swellable polymer matrix preferably having a dry thickness of at least 0.1 &mgr;m, and a pharmaceutically active compound, the polymer having pendant cationic and pendant zwitterionic groups. The active is usually an anionic compound such as a nucleic acid. The polymer is peferably formed from 2-methacyloyloxyethyl-2′-trimethylammoniumethyl phosphate inner salt, trialkylammoniumalkyl(meth)acrylate and a cross-linkable monomer such as &ohgr;(trialkoxysilyl)alkyl(meth)acrylate, optionally with a termonomer such as a higher alkyl(meth)acrylate. The stent is coated with polymer, cross-linked then contacted with a solution or dispersion of active compound in a solvent which swells the polymer wehereby the active is absorbed into the polymer matrix. The stent is delivered by usual means into a body lumen and the active is released over an extended period of time into the wall of the lumen and/or fluid flowing therein.

Abstract: An implant, usually a stent, has a coating of a cross-linked water swellable polymer matrix preferably having a dry thickness of at least 0.1 &mgr;m, and a pharmaceutically active compound, the polymer having pendant cationic and pendant zwitterionic groups. The active is usually an anionic compound such as a nucleic acid. The polymer is peferably formed from 2-methacyloyloxyethyl-2′-trimethylammoniumethyl phosphate inner salt, trialkylammoniumalkyl(meth)acrylate and a cross-linkable monomer such as &ohgr;(trialkoxysilyl)alkyl(meth)acrylate, optionally with a termonomer such as a higher alkyl(meth)acrylate. The stent is coated with polymer, cross-linked then contacted with a solution or dispersion of active compound in a solvent which swells the polymer wehereby the active is absorbed into the polymer matrix. The stent is delivered by usual means into a body lumen and the active is released over an extended period of time into the wall of the lumen and/or fluid flowing therein.